Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Gilead Licenses Long-Acting HIV Prevention Drug
Gilead signs deals with 6 generic drugmakers to sell HIV drug in low-income countries
Gilead Sciences said on Wednesday it has granted royalty-free licenses to six generic drug manufacturers to make and sell cheaper copycat versions of its HIV prevention medicine in 120 low and lower-middle income countries.
Gilead Licenses Long-Acting HIV Prevention Drug to Generics Firms
Gilead Sciences Inc. said it is licensing its twice-yearly experimental HIV prevention drug lenacapavir to six generics makers after coming under fire from HIV advocates who argued the company was prioritizing profit over patients.
Gilead Partners With Generics Developers to Provide HIV Drug to Low-Income Countries
Gilead Sciences is granting licenses to six companies to produce lenacapavir for pre-exposure prophylaxis, as well as for treating human immunodeficiency virus in heavily pre-treated adults with multidrug-resistant infections.
Gilead strikes deal to expand HIV drug access in 120 countries
If approved, the six manufacturers – Dr Reddy’s Laboratories Limited, Emcure, Eva Pharma, Ferozsons Laboratories Limited, Hetero, and Mylan (a subsidiary of Viatris) – will be able to produce and distribute generic versions of lenacapavir without paying royalties to Gilead.
Gilead expands access to PrEP HIV candidate in 120 countries
A new licensing agreement from Gilead Sciences and six generic drug manufacturers is poised to transform HIV prevention efforts
Gilead strikes voluntary licensing deals in poor countries for its pricey HIV drug
Gilead will license the HIV drug lenacapavir, a twice-yearly injectable, to six generic makers for 120 countries.
Gilead strikes licensing deals with 6 generics makers to boost access to long-acting HIV PrEP med
Gilead Sciences is wasting no time in promoting worldwide access to its twice-yearly pre-exposure prophylaxis (PrEP) HIV candidate lenacapavir. | The company will allow six generic manufacturers to make and sell its long-acting PrEP drug,
HIV prevention: why a new injectable drug could be such a breakthrough – podcast
HIV expert Linda-Gail Bekker talks to The Conversation Weekly about promising results from a trial of a new drug for HIV prevention.
Hetero Inks Voluntary Licensing Pact with Gilead for HIV Drug Lenacapavir
Hetero has partnered with Gilead Sciences to manufacture and distribute the HIV drug lenacapavir in 120 low- and middle-income countries, aiming to improve access to treatment and prevention. Lenacapavir,
Gilead Licenses HIV-prevention Drug To Generic Drugmakers
US pharmaceutical giant Gilead said Wednesday it had signed licensing deals with six generic drugmakers to produce and sell its HIV prevention medicine in lower-income countries.
GILD Grants Right for HIV PrEP Candidate to Six Generic Companies
Gilead Sciences GILD has entered into licensing deals with six pharmaceutical companies to manufacture and supply a cheaper version of its investigational drug, lenacapavir, for HIV prevention, also called pre-exposure prophylaxis (PrEP).
10h
Gilead inks pact with six generic drugmakers on long-acting HIV injectable, even as civil society oppose patent application
Six drugmakers sign agreements with Gilead Sciences to produce generic lenacapavir, a long-acting HIV drug, amid patent ...
Daily
11h
Gilead Sciences inks pacts with Dr Reddy's Labs, Emcure, Hetero and 3 others for HIV drug Lenacapavir
Gilead Sciences, Inc. has announced that it has signed non-exclusive, royalty-free voluntary licensing agreements with six ...
19h
Ferozsons Partners With Gilead Sciences to Produce HIV Medicine in Pakistan
Ferozsons Laboratories Limited (PSX: FEROZ) has entered into a non-exclusive voluntary license agreement with Gilead Sciences ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Trending now
US port strike ends
Helene's wake
Ex-Memphis cops guilty
To be closed indefinitely
Sentenced to 9 yrs in prison
Kirk becomes Category 4
Surveys Helene damage
Fifth recall within a year
California gang busted
Disrupt Russian hackers
'Rust' gets premiere date
Golf Hall of Famer dies
Ex-detective denied parole
OH gov. declares emergency
To hire 250,000 workers
Student loan plan ruling
5 Chinese nationals charged
FDA: No longer in shortage
Record heat bakes millions
Fruit fly brain mapped
US diagnostic errors study
Mortgage rate ticks up
US bans 2 Chinese firms
CA deepfakes law blocked
Expands online recruitment
Dream fire coach Wright
Israel strikes central Beirut
Feedback